| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics
|
Oct 22, 2026 | BUY |
Buy
-22.7% avg upside
27 analysts
|
$697.00
16.34% Upside
|
+1.1% | Β· |
|
EYPT
EyePoint Pharmaceuticals
|
Oct 20, 2026 | HOLD |
Buy
+3222.8% avg upside
21 analysts
|
$1.00
186.99% Upside
|
-24.4% | Β· |
|
VRDN
Viridian Therapeutics
|
Oct 08, 2026 | BUY |
Strong Buy
+42.6% avg upside
32 analysts
|
$38.00
53.94% Upside
|
+65.2% | Β· |
|
RYTM
Rhythm Pharmaceuticals
|
Oct 08, 2026 | BUY |
Strong Buy
+39.2% avg upside
23 analysts
|
$159.00
71.79% Upside
|
+28.3% | Β· |
|
KRYS
Krystal Biotech
|
Oct 08, 2026 | BUY |
Strong Buy
-15.2% avg upside
20 analysts
|
$400.00
20.29% Upside
|
-6.7% | Β· |
|
MIRM
Mirum Pharmaceuticals
|
Oct 08, 2026 | BUY |
Strong Buy
+48.1% avg upside
24 analysts
|
$155.00
82.44% Upside
|
+15.5% | Β· |
|
FDMT
4D Molecular Therapeutics
|
Aug 14, 2026 | BUY |
Strong Buy
+185.0% avg upside
17 analysts
|
$35.00
194.06% Upside
|
+0.3% | Β· |
|
MGTX
Meiragtx Holdings
|
Aug 13, 2026 | BUY |
Strong Buy
+166.7% avg upside
14 analysts
|
$27.00
184.54% Upside
|
-27.6% | Β· |
|
IRD
Opus Genetics
|
Aug 06, 2026 | BUY |
Strong Buy
+231.4% avg upside
25 analysts
|
$9.00
145.17% Upside
|
+7.0% | Β· |
|
OCUL
Ocular Therapeutix
|
Aug 03, 2026 | BUY |
Strong Buy
+253.9% avg upside
21 analysts
|
$30.00
330.32% Upside
|
-25.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.